Sam Brusco, Associate Editor02.17.23
Clinical-stage orthobiologics company ChitogenX has obtained, in partnership with Polytechnique Montréal, a $3.47 million grant from The Natural Sciences and Engineering Research Council of Canada (NSERC) and Prima Québec.
The four-year grant will be used to advance scientific development, expand scope of indications, develop new biomaterials for regenerative medicine, and accelerate commercial readiness of the company's flagship ORTHO-R technology platform.
"We are honored to receive funds from such prestigious organizations to accelerate the development of our proprietary technology platform. Regenerative medicine is a fast-growing sector, and these funds will help us position ChitogenX at the forefront of this dynamic sector", Philippe Deschamps, ChitogenX CEO told the press. "We look forward to our continued strong collaboration with Polytechnique Montréal and advancing scientific innovations for the greater good", added Deschamps.
"In the first year of the grant period we will focus on science that will enhance the potential applications of our ORTHO-R technology to the regenerative medicine industry such as delivering other biological products", continued Deschamps.
The ORTHO-R technology platform, invented at Polytechnique Montréal, was acquired in 2015 by ChitogenX, and the two entities have since closely collaborated to pursue its development.
The four-year grant will be used to advance scientific development, expand scope of indications, develop new biomaterials for regenerative medicine, and accelerate commercial readiness of the company's flagship ORTHO-R technology platform.
"We are honored to receive funds from such prestigious organizations to accelerate the development of our proprietary technology platform. Regenerative medicine is a fast-growing sector, and these funds will help us position ChitogenX at the forefront of this dynamic sector", Philippe Deschamps, ChitogenX CEO told the press. "We look forward to our continued strong collaboration with Polytechnique Montréal and advancing scientific innovations for the greater good", added Deschamps.
"In the first year of the grant period we will focus on science that will enhance the potential applications of our ORTHO-R technology to the regenerative medicine industry such as delivering other biological products", continued Deschamps.
The ORTHO-R technology platform, invented at Polytechnique Montréal, was acquired in 2015 by ChitogenX, and the two entities have since closely collaborated to pursue its development.